Prelude Therapeutics's market cap is currently $67.35M. The company's EPS TTM is $-0.41; its P/E ratio is ―; Prelude Therapeutics is scheduled to report earnings on August 14, 2025, and the estimated EPS forecast is $-0.36. See an overview of income statement, balance sheet, and cash flow financials.
